ARVINAS INC (ARVN)
US04335A1051 - Common Stock
ARVINAS INC
NASDAQ:ARVN (4/26/2024, 7:00:00 PM)
After market: 32.37 0 (0%)32.37
+0.77 (+2.44%)
Company Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 415 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The firm uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. The company develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). The company develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The firm develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.
Company Info
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511
P: 12035351456
CEO: John Houston
Employees: 415
Website: https://www.arvinas.com/
ARVN News
4 days ago - Market News VideoArvinas (ARVN) Shares Cross Below 200 DMA
5 days ago - Arvinas Inc.Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerNEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...
18 days ago - Investor's Business DailyBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsNovartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
18 days ago - Arvinas Inc.Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under...
ARVN Twits
Here you can normally see the latest stock twits on ARVN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
